Richard Silver to Respiratory Function Tests
This is a "connection" page, showing publications Richard Silver has written about Respiratory Function Tests.
Connection Strength
0.806
-
Management of Systemic-Sclerosis-Associated Interstitial Lung Disease. Rheum Dis Clin North Am. 2015 Aug; 41(3):439-57.
Score: 0.122
-
Relationship of main pulmonary artery diameter to pulmonary arterial pressure in scleroderma patients with and without interstitial fibrosis. J Comput Assist Tomogr. 2014 Mar-Apr; 38(2):163-8.
Score: 0.112
-
Pulmonary manifestations of scleroderma and mixed connective tissue disease. Clin Chest Med. 2010 Sep; 31(3):433-49.
Score: 0.088
-
Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. Semin Arthritis Rheum. 2010 Dec; 40(3):241-9.
Score: 0.086
-
Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum. 2005 Feb; 52(2):592-600.
Score: 0.060
-
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. Ann Rheum Dis. 2020 05; 79(5):618-625.
Score: 0.043
-
Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18. Arthritis Rheumatol. 2019 12; 71(12):2059-2067.
Score: 0.041
-
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 09; 4(9):708-719.
Score: 0.033
-
Recognition of pulmonary hypertension in the rheumatology community: lessons from a Quality Enhancement Research Initiative. Clin Exp Rheumatol. 2014 Nov-Dec; 32(6 Suppl 86):S-21-7.
Score: 0.027
-
Failure of the circulatory system limits exercise performance in patients with systemic sclerosis. Am J Med. 1993 Oct; 95(4):413-8.
Score: 0.027
-
Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol. 1993 May; 20(5):838-44.
Score: 0.026
-
High resolution computed tomography in early scleroderma lung disease. J Rheumatol. 1991 Oct; 18(10):1520-8.
Score: 0.024
-
Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med. 1990 May; 88(5):470-6.
Score: 0.021
-
Lung disease associated with progressive systemic sclerosis. Assessment of interlobar variation by bronchoalveolar lavage and comparison with noninvasive evaluation of disease activity. Am Rev Respir Dis. 1990 Feb; 141(2):301-6.
Score: 0.021
-
Lung involvement in systemic sclerosis. Rheum Dis Clin North Am. 1990 Feb; 16(1):199-216.
Score: 0.021
-
Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol. 2009 Apr; 36(4):773-80.
Score: 0.020
-
Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis. 2007 Dec; 66(12):1641-7.
Score: 0.017
-
Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006 Jun 22; 354(25):2655-66.
Score: 0.016